migraines

Salvia’s neuromodulation therapy for severe migraines shows promise
Salvia’s neuromodulation therapy for severe migraines shows promise
Clinical Trials Arena
Salvia
Medtech
neuromodulation
migraines
Flag link:
Lilly’s Migraine Drug Emgality Fails to Outperform Pfizer’s Nurtec
Lilly’s Migraine Drug Emgality Fails to Outperform Pfizer’s Nurtec
BioSpace
Eli Lilly
Emgality
Pfizer
Nurtec
migraines
Flag link:
NICE gives thumbs-up to Pfizer's migraine drug—but with lots of restrictions
NICE gives thumbs-up to Pfizer's migraine drug—but with lots of restrictions
Fierce Pharma
Biohaven
Pfizer
migraines
NICE
Nurtec
Vydura
Flag link:
With skin in the game, Satsuma's partner offers buyout to get migraine spray to market
With skin in the game, Satsuma's partner offers buyout to get migraine spray to market
Fierce Biotech
Satsuma Pharmaceuticals
Japan
migraines
Shin Nippon Biomedical
M&A
Flag link:
Satsuma peels off staff, cutting head count by 36% to save cash while searching for a deal
Satsuma peels off staff, cutting head count by 36% to save cash while searching for a deal
Fierce Biotech
Satsuma Pharmaceuticals
layoffs
migraines
STS101
Flag link:
Pfizer recalls migraine drug Nurtec ODT after millions of products lacked child resistant packaging
Pfizer recalls migraine drug Nurtec ODT after millions of products lacked child resistant packaging
USA Today
Pfizer
Nurtec ODT
migraines
packaging
product recalls
Flag link:
Royalty Pharma nabs $475M milestone from Pfizer upon migraine nasal spray OK
Royalty Pharma nabs $475M milestone from Pfizer upon migraine nasal spray OK
Endpoints
Pfizer
migraines
Royalty Pharma
Biohaven
zavegepant
Flag link:
Pfizer's Biohaven bet pays off again as migraine nasal spray wins approval
Pfizer's Biohaven bet pays off again as migraine nasal spray wins approval
BioSpace
Pfizer
Biohaven
FDA
migraines
nasal spray
zavegepant
Zavzpret
Flag link:
Pfizer cites positive results on nasal spray migraine treatment
Pfizer cites positive results on nasal spray migraine treatment
Medical Xpress
Pfizer
migraines
The Lancet
nasal spray
zavegepant
Flag link:
Satsuma in the red after 2nd phase 3 migraine flop spurs search for strategic alternatives
Satsuma in the red after 2nd phase 3 migraine flop spurs search for strategic alternatives
Fierce Biotech
Satsuma Pharmaceuticals
clinical trials
migraines
STS101
intra-nasal drug delivery
Flag link:
Eli Lilly ordered to pay $177M to rival Teva in migraine patent fight
Eli Lilly ordered to pay $177M to rival Teva in migraine patent fight
Fierce Pharma
Eli Lilly
legal
migraines
Ajovy
patents
Flag link:
With Pfizer sale in the rearview, Biohaven veers toward Kv7 platform following late-stage trial fails, delays
With Pfizer sale in the rearview, Biohaven veers toward Kv7 platform following late-stage trial fails, delays
Fierce Biotech
Pfizer
Biohaven
migraines
epilepsy
Flag link:
Satsuma peels off fresh strip of long-term migraine study data ahead of planned FDA filing
Satsuma peels off fresh strip of long-term migraine study data ahead of planned FDA filing
Fierce Pharma
Satsuma Pharmaceuticals
migraines
clinical trials
STS101
Flag link:
Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled
Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled
Fierce Pharma
Lundbeck
earnings
migraines
CGRPs
Vyepti
Flag link:
AbbVie files Qulipta for chronic migraine prevention
AbbVie files Qulipta for chronic migraine prevention
Pharmaforum
AbbVie
Qulipta
migraines
FDA
Flag link:
Zosano goes bankrupt after FDA rejects migraine drug delivery patch
Zosano goes bankrupt after FDA rejects migraine drug delivery patch
Fierce Pharma
Zosano Pharma
migraines
FDA
bankruptcy
Flag link:
After filing for bankruptcy, rejected migraine drug developer Zosano’s value more than halved
After filing for bankruptcy, rejected migraine drug developer Zosano’s value more than halved
Endpoints
Zosano Pharma
migraines
layoffs
FDA
Flag link:
Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs
Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs
BioPharma Dive
Pfizer
M&A
Biohaven
migraines
Flag link:
No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program
No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program
Fierce Pharma
Zosano Pharma
FDA
migraines
migraine patch
M207
Flag link:
As expected, FDA spikes down Axsome migraine med, but issues are 'addressable'
As expected, FDA spikes down Axsome migraine med, but issues are 'addressable'
Fierce Biotech
Axsome Therapeutics
migraines
FDA
AXS-07
Flag link:

Pages